CITED2 and coronary artery disorder: The majority of CITED2 mutations identified in CHD patients have minimal impact on CITED2′s ability to inhibit HIF-1α-driven transcriptional activity or to enhance TFAP2 transcriptional activity ex vivo [25,117,118,119,120,121,125].